Source of Global access disparity

{{Infobox concept | name = Global access disparity | subtitle = Health equity | Drivers = Price, manufacturing capacity, regulatory approval, coverage | Consequence = Availability tracks income between and within countries }} {{npov|talk=Framing of the access argument}} '''Global access disparity''' describes the uneven availability and affordability of incretin therapies. Availability tracks national income closely: approval, supply and coverage have concentrated in high-income markets, and the conditions these drugs treat are not so concentrated.{{r|who_obesity}} Four factors drive it. Price, set within markets rather than globally. Manufacturing capacity, which for peptides is capital-intensive and was constrained during the demand growth of the 2020s. Regulatory approval, granted jurisdiction by jurisdiction. And coverage, which determines affordability where a product is available at all.{{r|ada2024}} Disparity operates within countries as well as between them, along the ordinary lines of income and insurance status. See [[Prior authorisation]].{{r|kyle2021}} == Supply and manufacturing == Peptide manufacture at scale requires [[Solid-phase peptide synthesis|synthesis]] capacity, [[Preparative HPLC purification|preparative chromatography]] capacity, and [[Vial filling and stoppering|fill-finish]] capacity, each of which is capital-intensive and slow to build. Demand growth outpaced all three during the period these products expanded.{{r|usp1503}} Constrained supply is allocated by price and by contract, which concentrates it in markets able to pay. This is a market outcome rather than a policy decision, though policy shapes it. Capacity expansion has been substantial since, and the constraint has eased in some markets. Whether that translates into broader availability depends on price and approval rather than on capacity alone.{{r|ada2024}} == Approval and coverage == A product cannot be sold where it is not approved, and applications are filed where a market is expected. Approval therefore follows commercial assessment as much as need. See [[Regulatory status by jurisdiction]].{{r|ada2024}} Where approved, coverage decisions determine affordability. Weight-management indications are covered less often than glycaemic ones in many systems, and out-of-pocket cost at list price exceeds what most households can sustain for a chronic therapy. See [[Cost per milligram]].{{r|kyle2021}} The combination produces a pattern in which a person's access depends principally on where they live and what insurance they hold.{{r|who_obesity}} == Consequences and framing == One documented consequence is the growth of supply outside licensed channels, which carries the identity, content, sterility and provenance uncertainties this wiki documents throughout. See [[Peptide harm reduction]] and [[Grey market]].{{r|reports}} This article describes a pattern and its drivers. It does not argue for a policy: the question of what ought to be done about access is a political one, on which this wiki takes no position, and the neutrality tag reflects a live discussion about whether the framing here achieves that.{{r|who_obesity}} Research-use compounds are not approved for human administration, and nothing here is medical advice.{{r|usp1503}} == References == {{reflist}} <ref name="who_obesity">World Health Organization, ''Obesity and Overweight'' fact sheet and associated global health estimates.</ref> <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> <ref name="kyle2021">Kyle TK, Stanford FC. "Moving toward health policy that respects both science and people living with obesity." ''Nursing Clinics of North America'' 56(4):635–645 (2021). PMID 34749900.</ref> <ref name="usp1503">United States Pharmacopeia, General Chapter <1503>, ''Quality Attributes of Synthetic Peptide Drug Substances''.</ref> <ref name="reports">PeptidePedia Wiki community test-report tally, 2024–2026 (self-reported; see [[Project:Sourcing_guidelines]]).</ref> == See also == * [[Prior authorisation]] * [[Cost per milligram]] * [[Peptide harm reduction]] * [[Grey market]] * [[Regulatory status by jurisdiction]] {{DEFAULTSORT:Global access disparity}} [[Category:Health equity]] [[Category:Access and economics]] [[Category:Articles with a neutrality dispute]]